Xanodyne Pharmaceuticals, Inc.
Investment Company
| Name | Xanodyne Pharmaceuticals, Inc. |
|---|---|
| Sektor | Gesundheitswesen |
| Land | United States |
| Erstes Inv. |
2005 |
| Geschäftsfokus | Specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women's health and pain management |
| Kontakt |
7300 Turfway Road, Suite 300
Florence KY 41042 |
Xanodyne Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women’s health and pain management, today announced that the Bankruptcy Court for the District of Delaware has approved its bid to acquire the pharmaceutical assets of aaiPharma (PINK SHEET: AAIIQ). The deal terms included $209.25 million cash and additional non-cash consideration.
Weiter >>Presse
Apax Partners completes acquisition of TriZetto Group
The TriZetto Group, Inc. and Apax Partners announced today the closing of the merger pursuant to which funds advised by Apax Partners, together with minority investors BlueCross BlueShield of Tennessee and The Regence Group, acquired all of TriZetto’s common stock for $22 cash per share.
TriZetto agrees to be acquired by Apax Partners for $22 per share
The TriZetto Group, Inc. announced today that it has entered into a definitive agreement to be acquired and taken private by funds advised by Apax Partners.
Capio announces closing of purchase of Unilabs’ majority shareholders’ stake
Capio today announced that it has closed its purchase of the entire stake of registered and bearer shares and options of Unilabs from its majority shareholders.